Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AADvac1 in Non-Fluent Primary Progressive Aphasia
NCT03174886Phase 1Unknown
- Sponsor
- Axon Neuroscience
- Start
- Jul 2017
- Primary completion
- Nov 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AADvac1 in primary progressive aphasia, nonfluent variant (nfvPPA) (2 arms), sponsored by Axon Neuroscience. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 25 months and Immunogenicity at 24 months. Status: unknown.
02
Drugs
AADvac1
03
Conditions
primary progressive aphasia, nonfluent variant (nfvPPA)
Beyond the preview
Go deeper on NCT03174886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174886.